GeNeuro SA announces the liquidation of its French subsidiary GeNeuro Innovation SAS
Geneva, Switzerland, 16 July 2025 – 8:00 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Lyon Economic Activities Court has pronounced on July 15, 2025, the liquidation of GeNeuro Innovation SAS, the sole subsidiary of GeNeuro SA. This decision follows […]